NANOG and cancer: From synthetic DNA and RNAi approaches to indirect inhibition through targeting upstream regulators or mediators of proteasomal degradation, diverse strategies have shown efficacy in attenuating Nanog expression and mitigating CSC characteristics across various cancer types.